Medigene AG (ETR:MDG1 – Get Free Report)’s stock price shot up 2.5% on Wednesday . The stock traded as high as €1.59 ($1.71) and last traded at €1.58 ($1.70). 6,863 shares traded hands during trading, a decline of 98% from the average session volume of 306,207 shares. The stock had previously closed at €1.54 ($1.66).
Medigene Stock Up 2.5 %
The firm’s 50 day moving average price is €1.58 and its 200-day moving average price is €1.57. The company has a current ratio of 2.39, a quick ratio of 5.85 and a debt-to-equity ratio of 12.95. The company has a market cap of $12.02 million, a P/E ratio of -2.66, a price-to-earnings-growth ratio of 7.12 and a beta of 0.84.
About Medigene
Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company's end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its pipeline includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications; MDG10xx to treat multiple solid tumor; and MDG1011, a TCR-T immunotherapy candidate, which is in clinical development to treat blood cancer.
See Also
- Five stocks we like better than Medigene
- How to Calculate Inflation Rate
- Energy Transfer: Powering Data With Dividends and Diversification
- How to Profit From Growth Investing
- Qualcomm Stock Is Coiling for a Breakout
- Growth Stocks: What They Are, Examples and How to Invest
- Is Alphabet Too Cheap to Ignore After Its Recent Correction?
Receive News & Ratings for Medigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medigene and related companies with MarketBeat.com's FREE daily email newsletter.
